CRISPR Therapeutics
CRSP · Nasdaq · Switzerland
Share price · CRSP
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CRSP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026-9.8%
- 17 Sep 2026+9.8%
Nothing announced by CRSP that day or the session before.
- 19 Aug 2026+12.9%
Nothing announced by CRSP that day or the session before.
- 2 Jul 2026+8.0%
- 5 Jun 2026-9.0%
- 4 Jun 2026+9.4%
- 24 Apr 2026-11.6%
Nothing announced by CRSP that day or the session before.
- 10 Mar 2026-10.2%
Nothing announced by CRSP that day or the session before.
- 26 Feb 2026+11.8%
Nothing announced by CRSP that day or the session before.
- 13 Feb 2026+8.5%
Share of unusual movement by asset
For each asset, the share of CRSP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | BCL11A erythroid enhancer (gene editing)Gene therapy / editing | Sickle Cell DiseaseBeta-Thalassemia Transfusion-Dependent Beta Thalassemia | |
| Phase 2 | Factor XIRNA / oligonucleotide | Atherosclerotic Cardiovascular DiseaseVenous Thromboembolism | |
| Phase 1/2 | CD19Cell therapy | Systemic Lupus ErythematosusDiffuse Large B-Cell LymphomaFollicular Lymphoma | |
| Phase 1 | ANGPTL3Gene therapy / editing | Atherosclerotic Cardiovascular DiseaseSevere Hypertriglyceridemia |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (4)
June 2027 (2)
What to watch
What to watch
November 2027 (1)
What to watch
2029 (1)
December 2029 (1)
What to watch
2030 (1)
January 2030 (1)
What to watch
2033 (1)
December 2033 (1)
What to watch
2039 (1)
September 2039 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $13M | $72M | $192M+ $2.1B short-term inv. | $111M-$90M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $10M | $67M | $291M+ $2.1B short-term inv. | $91M-$84M operating cash flow | report ↗ |
| 2026-Q1 | $1.5M | $69M | $423M+ $2.0B short-term inv. | $123M-$109M operating cash flow | report ↗ |
| 2025-Q3 | $0.9M | $59M | $287M+ $1.6B short-term inv. | $106M-$85M operating cash flow | report ↗ |
| 2025-Q2 | $0.9M | $70M | $194M+ $1.5B short-term inv. | $209M-$114M operating cash flow | report ↗ |
| 2025-Q1 | $0.9M | $72M | $235M+ $1.6B short-term inv. | $136M-$54M operating cash flow | report ↗ |
| 2024-Q3 | $0.6M | $82M | $226M+ $1.7B short-term inv. | $86M-$107M operating cash flow | report ↗ |
| 2024-Q2 | $0.5M | $80M | $484M+ $1.5B short-term inv. | $126M-$96M operating cash flow | report ↗ |
| 2024-Q1 | $0.5M | $76M | $707M+ $1.4B short-term inv. | $117M$110M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $91M | $528M+ $1.2B short-term inv. | $112M-$40M operating cash flow | report ↗ |
| 2023-Q2 | $70M | $102M | $445M+ $1.3B short-term inv. | $78M-$133M operating cash flow | report ↗ |
| 2023-Q1 | $100M | $100M | $344M+ $1.5B short-term inv. | $53M$8.8M operating cash flow | report ↗ |
| 2022-Q3 | $0.1M | $117M | $494M+ $1.4B short-term inv. | $175M-$105M operating cash flow | report ↗ |
| 2022-Q2 | $0.2M | $123M | $497M+ $1.6B short-term inv. | $186M-$142M operating cash flow | report ↗ |
| 2022-Q1 | $0.9M | $118M | $684M+ $1.5B short-term inv. | $179M-$135M operating cash flow | report ↗ |
| 2021-Q3 | $0.8M | $105M | $1.0B+ $1.5B short-term inv. | $127M-$81M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $3.5M | $285M | $348M+ $1.6B short-term inv. | $145M-$345M operating cash flow | report ↗ |
For FY2025, CRISPR Therapeutics reported revenue of $3.51M, down 90.6% YoY, and R&D spend of $284.81M, down 11.2% YoY. Cash and cash equivalents were $347.56M, while cash, cash equivalents, and marketable securities totaled $1,975.8M at year-end, and the company reported a net loss of $581.6M.
Operationally, CASGEVY generated $116M in full-year 2025 revenue and $54M in Q4 2025, with 64 patient infusions during the year and 147 first cell collections. Pipeline advances included ongoing zugo-cel trials in autoimmune disease and B-cell malignancies, Phase 1b CTX310, CTX321 and CTX340 in IND/CTA-enabling studies, CTX460 in preclinical development, the CTX611 collaboration with Sirius, and CTX213 in diabetes. The company expects CASGEVY pediatric regulatory submissions to begin in H1 2026, CTX340 trial initiation in H1 2026, CTX460 trial initiation in mid-2026, and updates across several programs in H2 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $37M | $321M | $298M+ $1.6B short-term inv. | $92M-$143M operating cash flow | report ↗ |
| 2023-FY | $371M | $387M | $389M+ $1.3B short-term inv. | $38M-$260M operating cash flow | report ↗ |
| 2022-FY | $1.2M | $462M | $212M+ $1.6B short-term inv. | $163M-$496M operating cash flow | report ↗ |
| 2021-FY | $915M | $439M | $923M+ $1.5B short-term inv. | —$539M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 30 sales ($17.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | Kulkarni Samarth · director, Chief Executive Officer | Gift | 100,000 | — | — | Form 4 |
| 2026-11-04 | Sakhamuri Sivakesava · Chief Technical Officer | Award / grant (derivative) | 90,000 | — | — | Form 4 |
| 2026-11-04 | Sakhamuri Sivakesava · Chief Technical Officer | Award / grant (derivative) | 40,000 | — | — | Form 4 |
| 2026-10-26 | Patel Naimish · Chief Medical Officer | Award / grant (derivative) | 24,000 | — | — | Form 4 |
| 2026-10-26 | Kulkarni Samarth · director, Chief Executive Officer | Award / grant (derivative) | 57,500 | — | — | Form 4 |
| 2026-10-26 | KASINGER JAMES R. · General Counsel and Secretary | Award / grant (derivative) | 18,000 | — | — | Form 4 |
| 2026-10-26 | Silver Andrew Jacob · Chief Financial Officer | Award / grant (derivative) | 18,000 | — | — | Form 4 |
| 2026-10-26 | Patel Naimish · Chief Medical Officer | Award / grant (derivative) | 12,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 487 reporting institutions held 77.1M shares ($3.5B, 80.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | ARK Investment Management LLC | 11,313,623 | $538.2M |
| 2 | BlackRock, Inc. | 7,680,073 | $365.3M |
| 3 | Orbis Allan Gray Ltd | 6,106,011 | $290.5M |
| 4 | Capital World Investors | 4,725,037 | $224.8M |
| 5 | STATE STREET CORP | 3,982,500 | $189.4M |
| 6 | GSK plc | 3,220,627 | $153.2M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2,377,164 | $113.1M |
| 8 | SR One Capital Management, LP | 2,038,763 | $97.0M |
| 9 | FMR LLC | 1,954,694 | $93.0M |
| 10 | Amova Asset Management Americas, Inc. | 1,853,875 | $88.2M |
| 11 | Sumitomo Mitsui Trust Group, Inc. | 1,853,875 | $88.2M |
| 12 | UBS Group AG | 1,762,530 | $83.8M |
| 13 | TWO SIGMA INVESTMENTS, LP | 1,483,051 | $70.5M |
| 14 | EcoR1 Capital, LLC | 1,389,276 | $66.1M |
| 15 | Capital International Investors | 1,186,794 | $56.5M |